[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Clark Laboratories, Inc. (dba,Trinity Biotech USA)\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":96},{"warningLetters":4,"total":95},[5,31,54,74],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3447,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-03-22T15:00:00Z\">03\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-18T04:00:00Z\">03\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolyte-laboratories-llc-603584-03182021\">BioLyte Laboratories, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin J. DeVisser\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLyte Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>310 Northern Dr. NW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grand Rapids\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49534\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>March 18, 2021\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case# 603584\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. DeVisser:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BioLyte Laboratories, LLC, FEI 3013171766, located at 310 Northern Dr. NW, Grand Rapids, MI, from December 9 to 18, 2019 and on February 13, 2020.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and misbranding regulations for dietary supplements. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR, parts 210 and 211) and 21 CFR 101, respectively. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). Introduction or delivery for introduction of adulterated products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures the products “\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray,” which are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). In addition, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” are also misbranded under section 502 of the FD&amp;C Act, 21 U.S.C. 352. Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301(a) and 502 of the FD&amp;C Act, 21 U.S.C. 331(a) and 352. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (CGMP) Charges\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your January 9, 2020, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You released your over-the-counter (OTC) topical drug products without adequate quality control testing, including but not limited to the identity and strength of each active ingredient. For example, identity and potency testing is not performed for the active ingredient in your Topical Pain Relief drug product (Menthol 4%) before release.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, you do not know whether they conform to finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you were in the process of setting up testing with FDA registered laboratories that have the capability to test for identity and potency of your active pharmaceutical ingredients.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide adequate justification for the limited testing you proposed in your response.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\t\u003Cli>Microbiological testing methods that are capable of recovering bioburden in your product and determining whether any microorganisms are objectionable relative to the product’s intended use, route of administration, and patient (i.e., consumer) population. The suitability of all test methods should be verified under actual conditions of use.\u003C\u002Fli>\n\t\u003Cli>A commitment to testing each batch, using qualified methods to ensure conformance to finished product specifications before final disposition.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed within the United States and within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not perform at least one specific identity test for each component used in production of your OTC and Homeopathic drug products. During the inspection, you stated that you do not perform identity testing of incoming drug components, nor verify or validate supplier’s test results as reported on the Certificates of Analysis (COAs).\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your raw material receiving procedure would be modified to include identity testing of active pharmaceutical ingredients (API), and also stated that you had contracted a laboratory to perform identity testing of all future API received at your site.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not address your failure to test all drug components, including both active and inactive ingredients used in your OTC and homeopathic drug products, for identity and other appropriate specifications before use. Further, your response did not address the failure to establish the reliability of your component supplier’s test analyses at appropriate intervals. You did not address the effect of this deficiency on the quality of all your distributed drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any testing results on your supplier’s COA in lieu of testing each component lot for purity, strength, and quality, specify in detail how you will first establish the reliability and consistency of your supplier’s test results for these attributes through initial validation (followed by periodic re-validation). In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that perform testing of the components you use in manufacturing your drug products.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\u003C\u002Fli>\n\t\u003Cli>A retrospective assessment of all drug product batches within expiry and in distribution within the United States, manufactured using components that were not adequately tested and controlled.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have appropriate stability data to support the 3-year expiration date for the OTC Pain Relief drug product that you manufacture.\u003C\u002Fp>\n\n\u003Cp>During the inspection, you provided evidence that you perform a visual, odor, and pH check of your finished drug product in your stability program. However, you failed to adequately demonstrate that the chemical, physical and microbiological properties of your drug products remain acceptable throughout the labeled 3-year expiry period. Therefore, there is inadequate assurance that your drug products can meet their label claims through their expiration period.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you were working with your client to determine a justifiable shelf life for this product, and you committed to test the drug product based on your standard real-time stability timeline as detailed in your updated stability procedure.\u003C\u002Fp>\n\n\u003Cp>Your response cannot be fully evaluated because you did not include your stability study test results used to determine if each of your commercial drug products will meet specifications at the end of the labeled expiration period.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment, corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before you permit distribution\u003Cbr>\n&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if shelf-life claims remain valid\u003Cbr>\n&nbsp; o A detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Charges\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including websites listed on your product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Used as an antimicrobial to help treat minor skin wounds, burns, infections . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“USEFUL FOR WOUNDS, BURNS, BANDAGES, AND MORE . . . TOPICALLY USED AGAINST INFECTIONS . . . TOPICALLY USED AGAINST SEVERAL SKIN CONDITIONS (Hives, Rashes, eczema, diaper rash).”\u003C\u002Fli>\n\t\u003Cli>“The silver gel may reduce scarring, age spots, and may aid in healing of wounds, bed sores, burns, and diabetic ulcers.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“For topical use, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel is used to resolve a wide variety of skin problems . . . ideal for cuts, burns, serious wounds . . . [s]ilver interferes with the energy sources of bacteria, virus and other microbes . . . [u]ltimately it kills bacteria and reduces viral replication.”\u003C\u002Fli>\n\t\u003Cli>“Recommended uses . . . Wound care[,] Diaper rash[,] . . . Fungal infections . . ..”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Silver Liquid Supplement”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]an be used internally and topically to address a wide variety of health issues . . . demonstrates antiviral, antibacterial, and antifungal effects for virtually every surface and tissue in the body.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Uses . . . For temporary relief of occasional: . . . minor aches and pains of muscles and joints associated with simple backache - arthritis – bruises - strains”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> is a gentle, clear, odourless, 97% natural pain relief gel for skin irritations, bruising, soreness, muscle strains, back pain, knee pain, and arthritis-related pain.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Pain Relief Cream with \u003Cstrong>(b)(4)\u003C\u002Fstrong> rejuvenating CBD” . . . Uses . . . For temporary relief of occasional: . . . minor aches and pains . . . Stiffness of muscles, joints and tissues”\u003C\u002Fli>\n\t\u003Cli>“Arnica . . . It is known to reduce swelling and decrease pain . . . Belladonna . . . soothe joint pain and general nerve pain . . . Hypericum . . . treat wounds on the skin and improve tissue generation . . . Ruta Graveolens . . . known to treat neuromuscular problems such as joint paint (sic), strains, and arthritis . . . Bryonia . . . treat pain associated with sprains and bruises . . . Actaea Spicata . . . traditionally used for the treatment of various ailments such as rheumatism, inflammation, and nerve diseases . . . Actaea Racemosa . . . used in Native American culture to heal chorea, dropsy, lumbago, and other nervous disorders . . . Rhododendron Tometosum . . . used first and foremost as a first-aid remedy to prevent infection but also remedies bruises, insect stings and bites, puncture wounds, cuts, grazes, and scrapes . . . Rhododendron Chrysanthum . . . effective in healing conditions like splitting pain in the ligaments, joint tissue and cartilage as well as swelling and rheumatic pains . . . Salicylicum Acidum . . . know to treat rheumatism, coryza, psoriasis, acne, and general skin irritation . . . Bellis Perennis . . . used to treat bruises, muscle pain, cutaneous wounds, rheumatism, eczema, boils and skin inflammation . . . “\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Spray pain away . . . Magnesium Oil Spray . . . Research shows magnesium can ease stress, anxiety, muscle\u002Fjoint pain, and headaches, and aid in promoting restful sleep. . . . Immediate Relief”\u003C\u002Fli>\n\t\u003Cli>“This highly portable spray is a must-have post workout. Ultra-absorbent, odorless, and non-greasy, simply spray this magnesium chloride oil on your skin. . . . I am an athletic person and can tend to overuse and over do at time . (sic) . . . I feel confident that I have this product to help with the occasional flare up in my ankle . (sic) It alleviates the soreness rapidly” . . . I woke with a headache one morning and spray some on my temples and the headache went away immediately! I have very tense muscles in my neck and shoulders. I’ve tried so many different muscle rubs and creams, but this magnesium spray works better than anything I’ve ever tried! . . . No more joint pain . . . I have tendenitics\u002Farthritis (sic) as a result of injurying (sic) the tendons on the thumb of my right hand years ago. Over the years I’ve had acupuncture treatments, and other ontiments (sic) to help with the pain that only offered temporary relief. . . . However, after using the magnesium spray, for the first time in years, I finally have relief from the persistent pain I’d wake up to in the mornings. . . . IT WORKS . . . I have achilles tendonitis and I spray it on before I go to bed. I am now able to sleep at night.””\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>External Analgesic Drug Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, your products “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” are drugs intended for use as external analgesics. We are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream”, or “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” are generally recognized as safe and effective (GRASE) for use under the conditions suggested, recommended, or prescribed in their labeling. Thus, these external analgesic drug products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). New drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are nonprescription drugs governed by and lawfully marketed under section 505G\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of the FD&amp;C Act, among other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for any of these external analgesic products, nor are they nonprescription drugs eligible for marketing under section 505G of the FD&amp;C Act, as described below. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act governs nonprescription drugs marketed without an approved application (commonly referred to as over-the-counter or “OTC” drugs), such as your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under section 505G, eligible nonprescription drug products need not have an approved application for lawful marketing, if certain conditions are met. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product is not eligible for marketing without an approved application under section 505G. Specifically, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product does not meet the applicable conditions of section 505G(a)(1) or (2) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1) or (2), under which nonprescription drugs marketed without an approved application are deemed GRASE and not considered “new drugs” by operation of law. Among these conditions is that a drug conforms with the general requirements for nonprescription drugs and that it conforms with the requirements for nonprescription use of a final monograph issued under 21 CFR part 330 or, for drugs classified in Category I for safety and effectiveness under a tentative final monograph (TFM), that a drug conforms with the proposed requirements of such TFM. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product does not meet these conditions, notably because the product's active ingredient, magnesium (as described below), was not an active ingredient in any applicable final monograph or TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>We note that your products “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” are labeled as homeopathic drug products. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval. As noted above, your \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products are “new drugs” under section 201(p) of the FD&amp;C Act and are not the subject of an FDA-approved application. Moreover, these products are not eligible to be marketed without an approved application under section 505G of the FD&amp;C Act, because under the CARES Act, section 505G does not apply to homeopathic drugs.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Even if your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products were governed by section 505G, they would not meet the conditions for marketing without an approved application under section 505G, notably because the products’ active ingredient cannabidiol (CBD), as described below, was not an active ingredient in any applicable final monograph or TFM.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>CBD-containing drug products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your products “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” are labeled to contain CBD.\u003C\u002Fp>\n\n\u003Cp>Although CBD is labeled as an inactive ingredient in the labels of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” products, the labeling for these products clearly represent CBD as an active ingredient.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> For instance, your product label for “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” features the statement, “Pain Relief Cream with \u003Cstrong>(b)(4)\u003C\u002Fstrong> rejuvenating CBD,” and the product label for “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” features the statement, “CBD 560mg.” As noted above, CBD was not an active ingredient in any applicable final monograph or TFM, for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&amp;C Act. In particular, such product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects\u003Csup>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD, however, has known pharmacological activity with demonstrated risks.\u003Csup>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> It is unknown whether the levels of CBD used in your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” and “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Therapeutic Pain Gel” products have pharmacological activity or pose any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Moreover, as explained above, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” products are labeled as homeopathic drug products and thus are ineligible for marketing without an approved application under section 505G of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Magnesium-containing drug product\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Similarly, although your firm does not specifically list magnesium oil as an active ingredient on the label of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product, the product labeling clearly represents magnesium as an active ingredient. For instance, the label includes the statement, “[r]esearch shows magnesium can ease stress, anxiety, muscle\u002Fjoint pain, and headaches, and aid in promoting restful sleep.” Because as noted magnesium was not an active ingredient under any applicable final monograph or TFM, your \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product would not meet the conditions for lawful marketing without an approved application under section 505G(a)(1) or (2). This product would also be ineligible for marketing without an approved application under section 505G(a)(1) or (2) because its labeling is inconsistent with the conditions applicable to OTC external analgesics, in that the product claims regarding easing of stress and anxiety reflect indications not included under the external analgesic TFM.\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition to failing to meet the conditions for marketing under section 505G(a)(1) or (2) of the FD&amp;C Act, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product does not meet the other conditions under section 505G under which nonprescription drug products can be lawfully marketed without an approved application. Specifically, it does not satisfy the requirements under sections 505G(a)(3)\u003Csup>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> nor is its marketing permitted by an order issued under section 505G(b)(1).\u003Csup>\u003Cem>\u003Cstrong>14 \u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products also cannot meet such other marketing conditions because they are inapplicable, given that these products are labeled as homeopathic drug products which, again, are not governed by section 505G.\u003C\u002Fp>\n\n\u003Cp>For the above reasons, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a), 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Silver-containing Drug Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on their labeling, your products “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement” are drugs that contain silver as an active ingredient. Further, these products lack an approved application and are made available for purchase by consumers without a prescription, i.e., OTC. Accordingly, these products are subject to section 505G of the FD&amp;C Act, which as noted above governs nonprescription drugs marketed without an approved application. Specifically, your silver products fall under section 505G(a)(5) of the FD&amp;C Act, because under a final determination issued under 21 CFR part 330, as published in the Federal Register on August 17, 1999,\u003Csup>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> the Agency has determined that no silver containing OTC drugs are GRASE under section 201(p)(1) of the FD&amp;C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&amp;C Act to be lawfully marketed.\u003Csup>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>New drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are eligible to be marketed without an approved application under section 505G of the FD&amp;C Act, among other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” drug products. Nor are these products eligible to be marketed without an approved application under section 505G of the FD&amp;C Act. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” products are misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 502 and 301(a) of the FD&amp;C Act, 21 U.S.C. 352 and 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained above, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray,” \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement\" products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section, and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. Consequently, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). In addition, your silver-containing products \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement\" are misbranded under section 502 of the FD&amp;C Act by virtue of 21 CFR 310.548(b).\u003Csup>\u003Cem>\u003Cstrong>17\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Furthermore, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products are also misbranded under section 502(a) of the FD&amp;C Act because the labeling of these products is false and misleading for several reasons. First, the labeling for your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products identifies CBD as an inactive ingredient, but represents CBD as having purported active pharmacological properties such as pain relief, among others. Even if CBD could be considered an inactive ingredient in these products, the prominent featuring of CBD on the labeling on your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream” products causes the products to be misbranded under section 502(a) of the FD&amp;C Act, which deems a drug to be misbranded if its labeling is “false or misleading in any particular,” and under 21 CFR 201.10(c)(4). Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason … [of] the featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.” Similarly, although the labeling for your \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product does not specifically list magnesium oil as an active ingredient, your labeling claims represent magnesium as an active ingredient, as described above, and thus this product is also misbranded under section 502(a) of the FD&amp;C Act and 21 CFR 201.10(c)(4).\u003C\u002Fp>\n\n\u003Cp>Accordingly, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Gel with Aloe,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Therapeutic Pain Gel,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Pain Relief Cream,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” products are misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 502 and 301(a) of the FD&amp;C Act, 21 U.S.C. 352 and 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement (even if not considered an unapproved new drug and\u002For a misbranded drug), \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Water, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver products are misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101, as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Water products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. 343 (e)(1)] in that the label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the products do not present nutrition information on the labeling as required by 21 CFR 101.36 and 21 CFR 101.9. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver products labels fail to list the serving sizes which include 1 teaspoon twice daily for people under 75 pounds (lbs.) and 2 teaspoons twice daily for people over 75 lbs. If the product is for persons within more than one group, the quantitative amount and percent of Daily Value for each group shall be presented in separate columns in accordance with 21 CFR 101.36(b)(2)(iii)(E)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>3. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. 343(s)(2)(B)] because the product labels do not include a statement of identity as a “dietary supplement” as required by 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>4. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>Additionally,\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver product labels bear the following statement: “DV (Daily Value) based on a 2,000 calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, added sugars, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver Liquid Supplement, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Silver product labels are using an incorrect version of the FDA disclaimer. This FDA disclaimer is only required when certain statements as mentioned in 21 CFR 101.93(f) are declared on the label.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP consultant recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified third party perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the effectiveness of your corrective actions and preventive actions.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for fully resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>Any drug marketed by your firm must conform with all applicable requirements of the FD&amp;C Act, including those outlined in the Unapproved New Drug and Misbranding Charges section of this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Failure to promptly correct any violations may result in legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please submit your response via email to ORAPHARM3_RESPONSES@FDA.HHS.GOV.\u003C\u002Fp>\n\n\u003Cp>Attention: Brian D. Garthwaite, Ph. D.\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please contact Dr. Garthwaite at \u003Cspan>(612) 758-7132\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Art O. Czabaniuk\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Section 505G of the FD&amp;C Act was added under title III, subtitle F (\"Over-the-Counter Drugs\") of the CARES Act, Pub. L 116-136 (March 27, 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Your “\u003Cstrong>(b)(4) \u003C\u002Fstrong>Magnesium Oil Spray” is made available for purchase by consumers without a prescription.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> We note that OTC drug products intended for external analgesic indications, such as the temporary relief of pain, were addressed in the Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, magnesium was not included as an active ingredient under this TFM.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See section 3853(a) of the CARES Act, Pub. L. 116-136 (March 27, 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5\u003C\u002Fstrong> See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, CBD was not included as an active ingredient under this TFM. 6 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7\u003C\u002Fstrong> 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity\".\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8\u003C\u002Fstrong> See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload\u003C\u002Fa>, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9\u003C\u002Fstrong> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10\u003C\u002Fstrong> See 21 CFR 330.1(e).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11\u003C\u002Fstrong> For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver&nbsp;injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, easing of stress and anxiety were not indications included under this TFM.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>13 \u003C\u002Fstrong>\u003C\u002Fem>Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including labeling conditions, and comply with all other applicable requirements for nonprescription drugs. Drugs containing magnesium as an active ingredient were not classified under any applicable TFM as Category III for safety or effectiveness. Thus, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product does not meet the conditions under section 505G(a)(3) for lawful marketing absent an approved application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Magnesium Oil Spray” product is not the subject of an order issued under section 505G(b)(1) of the FD&amp;C Act, 21 U.S.C 355h(b)(1), under which it is considered GRASE and can be lawfully marketed without an approved application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> See 64 FR 44653, 44658 (Aug. 17, 1999) establishing 21 CFR 310.548(a), which states in relevant part that \"…there is a lack of adequate data to establish general recognition of the safety and effectiveness of colloidal silver ingredients or silver salts for OTC use in the treatment or prevention of any disease. These ingredients and salts include, but are not limited to, silver proteins, mild silver protein, strong silver protein, silver, silver ion, silver chloride, silver cyanide, silver iodide, silver oxide, and silver phosphate\".\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> Id. at 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act\".\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>17\u003C\u002Fstrong>\u003C\u002Fem> See 64 FR 44653, 44658 (Aug. 17, 1999), establishing 21 CFR 310.548, which at 21 CFR 310.548(b) states that \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act\" (emphasis added).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKevin J. DeVisser\n\nRecipient Title\n\nChief Executive Officer\n\nBioLyte Laboratories, LLC\n\n310 Northern Dr. NW\n\nGrand Rapids, MI 49534\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nMarch 18, 2021\n\nWARNING LETTER\n\nCase# 603584\n\nDear Mr. DeVisser:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BioLyte Laboratories, LLC, FEI 3013171766, located at 310 Northern Dr. NW, Grand Rapids, MI, from December 9 to 18, 2019 and on February 13, 2020.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and misbranding regulations for dietary supplements. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR, parts 210 and 211) and 21 CFR 101, respectively. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). Introduction or delivery for introduction of adulterated products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nYour firm manufactures the products “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray,” which are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). In addition, your “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” are also misbranded under section 502 of the FD&C Act, 21 U.S.C. 352. Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301(a) and 502 of the FD&C Act, 21 U.S.C. 331(a) and 352. These violations are described in more detail below.\n\nCurrent Good Manufacturing Practice (CGMP) Charges\n\nWe reviewed your January 9, 2020, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYou released your over-the-counter (OTC) topical drug products without adequate quality control testing, including but not limited to the identity and strength of each active ingredient. For example, identity and potency testing is not performed for the active ingredient in your Topical Pain Relief drug product (Menthol 4%) before release.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, you do not know whether they conform to finished product specifications and are suitable for release to consumers.\n\nIn your response, you stated that you were in the process of setting up testing with FDA registered laboratories that have the capability to test for identity and potency of your active pharmaceutical ingredients.\n\nYour response is inadequate. You did not provide adequate justification for the limited testing you proposed in your response.\n\nIn response to this letter, provide:\n\nA list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\nMicrobiological testing methods that are capable of recovering bioburden in your product and determining whether any microorganisms are objectionable relative to the product’s intended use, route of administration, and patient (i.e., consumer) population. The suitability of all test methods should be verified under actual conditions of use.\n\nA commitment to testing each batch, using qualified methods to ensure conformance to finished product specifications before final disposition.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed within the United States and within expiry as of the date of this letter.\n\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou did not perform at least one specific identity test for each component used in production of your OTC and Homeopathic drug products. During the inspection, you stated that you do not perform identity testing of incoming drug components, nor verify or validate supplier’s test results as reported on the Certificates of Analysis (COAs).\n\nIn your response, you stated that your raw material receiving procedure would be modified to include identity testing of active pharmaceutical ingredients (API), and also stated that you had contracted a laboratory to perform identity testing of all future API received at your site.\n\nYour response is inadequate. You did not address your failure to test all drug components, including both active and inactive ingredients used in your OTC and homeopathic drug products, for identity and other appropriate specifications before use. Further, your response did not address the failure to establish the reliability of your component supplier’s test analyses at appropriate intervals. You did not address the effect of this deficiency on the quality of all your distributed drug products.\n\nIn response to this letter, provide:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any testing results on your supplier’s COA in lieu of testing each component lot for purity, strength, and quality, specify in detail how you will first establish the reliability and consistency of your supplier’s test results for these attributes through initial validation (followed by periodic re-validation). In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of your program for qualifying and overseeing contract facilities that perform testing of the components you use in manufacturing your drug products.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\n\nA retrospective assessment of all drug product batches within expiry and in distribution within the United States, manufactured using components that were not adequately tested and controlled.\n\n3. Your firm failed to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYou do not have appropriate stability data to support the 3-year expiration date for the OTC Pain Relief drug product that you manufacture.\n\nDuring the inspection, you provided evidence that you perform a visual, odor, and pH check of your finished drug product in your stability program. However, you failed to adequately demonstrate that the chemical, physical and microbiological properties of your drug products remain acceptable throughout the labeled 3-year expiry period. Therefore, there is inadequate assurance that your drug products can meet their label claims through their expiration period.\n\nIn your response, you stated that you were working with your client to determine a justifiable shelf life for this product, and you committed to test the drug product based on your standard real-time stability timeline as detailed in your updated stability procedure.\n\nYour response cannot be fully evaluated because you did not include your stability study test results used to determine if each of your commercial drug products will meet specifications at the end of the labeled expiration period.\n\nIn response to this letter, provide:\n\nA comprehensive assessment, corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before you permit distribution\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if shelf-life claims remain valid\n\no A detailed definition of the specific attributes to be tested at each station (timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nUnapproved New Drug and Misbranding Charges\n\nUnapproved New Drug Violations\n\nYour “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including websites listed on your product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\n\n“(b)(4) Silver Gel,”\n\n“Used as an antimicrobial to help treat minor skin wounds, burns, infections . . .”\n\n“(b)(4) Silver Gel”\n\n“USEFUL FOR WOUNDS, BURNS, BANDAGES, AND MORE . . . TOPICALLY USED AGAINST INFECTIONS . . . TOPICALLY USED AGAINST SEVERAL SKIN CONDITIONS (Hives, Rashes, eczema, diaper rash).”\n\n“The silver gel may reduce scarring, age spots, and may aid in healing of wounds, bed sores, burns, and diabetic ulcers.”\n\n“(b)(4) Silver Gel with Aloe”\n\n“For topical use, (b)(4) Silver Gel is used to resolve a wide variety of skin problems . . . ideal for cuts, burns, serious wounds . . . [s]ilver interferes with the energy sources of bacteria, virus and other microbes . . . [u]ltimately it kills bacteria and reduces viral replication.”\n\n“Recommended uses . . . Wound care[,] Diaper rash[,] . . . Fungal infections . . ..”\n\n“(b)(4) Silver Liquid Supplement”\n\n“[C]an be used internally and topically to address a wide variety of health issues . . . demonstrates antiviral, antibacterial, and antifungal effects for virtually every surface and tissue in the body.”\n\n“(b)(4) Therapeutic Pain Gel”\n\n“Uses . . . For temporary relief of occasional: . . . minor aches and pains of muscles and joints associated with simple backache - arthritis – bruises - strains”\n\n“(b)(4) is a gentle, clear, odourless, 97% natural pain relief gel for skin irritations, bruising, soreness, muscle strains, back pain, knee pain, and arthritis-related pain.”\n\n“(b)(4) Pain Relief Cream”\n\n“Pain Relief Cream with (b)(4) rejuvenating CBD” . . . Uses . . . For temporary relief of occasional: . . . minor aches and pains . . . Stiffness of muscles, joints and tissues”\n\n“Arnica . . . It is known to reduce swelling and decrease pain . . . Belladonna . . . soothe joint pain and general nerve pain . . . Hypericum . . . treat wounds on the skin and improve tissue generation . . . Ruta Graveolens . . . known to treat neuromuscular problems such as joint paint (sic), strains, and arthritis . . . Bryonia . . . treat pain associated with sprains and bruises . . . Actaea Spicata . . . traditionally used for the treatment of various ailments such as rheumatism, inflammation, and nerve diseases . . . Actaea Racemosa . . . used in Native American culture to heal chorea, dropsy, lumbago, and other nervous disorders . . . Rhododendron Tometosum . . . used first and foremost as a first-aid remedy to prevent infection but also remedies bruises, insect stings and bites, puncture wounds, cuts, grazes, and scrapes . . . Rhododendron Chrysanthum . . . effective in healing conditions like splitting pain in the ligaments, joint tissue and cartilage as well as swelling and rheumatic pains . . . Salicylicum Acidum . . . know to treat rheumatism, coryza, psoriasis, acne, and general skin irritation . . . Bellis Perennis . . . used to treat bruises, muscle pain, cutaneous wounds, rheumatism, eczema, boils and skin inflammation . . . “\n\n“(b)(4) Magnesium Oil Spray”\n\n“Spray pain away . . . Magnesium Oil Spray . . . Research shows magnesium can ease stress, anxiety, muscle\u002Fjoint pain, and headaches, and aid in promoting restful sleep. . . . Immediate Relief”\n\n“This highly portable spray is a must-have post workout. Ultra-absorbent, odorless, and non-greasy, simply spray this magnesium chloride oil on your skin. . . . I am an athletic person and can tend to overuse and over do at time . (sic) . . . I feel confident that I have this product to help with the occasional flare up in my ankle . (sic) It alleviates the soreness rapidly” . . . I woke with a headache one morning and spray some on my temples and the headache went away immediately! I have very tense muscles in my neck and shoulders. I’ve tried so many different muscle rubs and creams, but this magnesium spray works better than anything I’ve ever tried! . . . No more joint pain . . . I have tendenitics\u002Farthritis (sic) as a result of injurying (sic) the tendons on the thumb of my right hand years ago. Over the years I’ve had acupuncture treatments, and other ontiments (sic) to help with the pain that only offered temporary relief. . . . However, after using the magnesium spray, for the first time in years, I finally have relief from the persistent pain I’d wake up to in the mornings. . . . IT WORKS . . . I have achilles tendonitis and I spray it on before I go to bed. I am now able to sleep at night.””\n\nExternal Analgesic Drug Products\n\nBased on the above labeling claims, your products “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” are drugs intended for use as external analgesics. We are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream”, or “(b)(4) Magnesium Oil Spray” are generally recognized as safe and effective (GRASE) for use under the conditions suggested, recommended, or prescribed in their labeling. Thus, these external analgesic drug products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). New drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are nonprescription drugs governed by and lawfully marketed under section 505G1 of the FD&C Act, among other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for any of these external analgesic products, nor are they nonprescription drugs eligible for marketing under section 505G of the FD&C Act, as described below. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nSection 505G of the FD&C Act governs nonprescription drugs marketed without an approved application (commonly referred to as over-the-counter or “OTC” drugs), such as your “(b)(4) Magnesium Oil Spray” product.2 Under section 505G, eligible nonprescription drug products need not have an approved application for lawful marketing, if certain conditions are met. However, your “(b)(4) Magnesium Oil Spray” product is not eligible for marketing without an approved application under section 505G. Specifically, your “(b)(4) Magnesium Oil Spray” product does not meet the applicable conditions of section 505G(a)(1) or (2) of the FD&C Act, 21 U.S.C. 355h(a)(1) or (2), under which nonprescription drugs marketed without an approved application are deemed GRASE and not considered “new drugs” by operation of law. Among these conditions is that a drug conforms with the general requirements for nonprescription drugs and that it conforms with the requirements for nonprescription use of a final monograph issued under 21 CFR part 330 or, for drugs classified in Category I for safety and effectiveness under a tentative final monograph (TFM), that a drug conforms with the proposed requirements of such TFM. Your “(b)(4) Magnesium Oil Spray” product does not meet these conditions, notably because the product's active ingredient, magnesium (as described below), was not an active ingredient in any applicable final monograph or TFM.3\n\nWe note that your products “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” are labeled as homeopathic drug products. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval. As noted above, your \"(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products are “new drugs” under section 201(p) of the FD&C Act and are not the subject of an FDA-approved application. Moreover, these products are not eligible to be marketed without an approved application under section 505G of the FD&C Act, because under the CARES Act, section 505G does not apply to homeopathic drugs.4 Even if your “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products were governed by section 505G, they would not meet the conditions for marketing without an approved application under section 505G, notably because the products’ active ingredient cannabidiol (CBD), as described below, was not an active ingredient in any applicable final monograph or TFM.5\n\nCBD-containing drug products\n\nYour products “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” are labeled to contain CBD.\n\nAlthough CBD is labeled as an inactive ingredient in the labels of your “(b)(4) Pain Relief Cream” and “(b)(4) Therapeutic Pain Gel” products, the labeling for these products clearly represent CBD as an active ingredient.6 For instance, your product label for “(b)(4) Pain Relief Cream” features the statement, “Pain Relief Cream with (b)(4) rejuvenating CBD,” and the product label for “(b)(4) Therapeutic Pain Gel” features the statement, “CBD 560mg.” As noted above, CBD was not an active ingredient in any applicable final monograph or TFM, for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&C Act.\n\nFurthermore, even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&C Act. In particular, such product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.7 A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).8 CBD has no known functional role as an inactive ingredient in a finished drug product. Additionally, an inactive ingredient should not exert pharmacological effects9 and must be safe when used at the intended dosage.10 CBD, however, has known pharmacological activity with demonstrated risks.11 It is unknown whether the levels of CBD used in your “(b)(4) Pain Relief Cream” and “(b)(4) Therapeutic Pain Gel” products have pharmacological activity or pose any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Moreover, as explained above, your “(b)(4) Pain Relief Cream” and “(b)(4) Therapeutic Pain Gel” products are labeled as homeopathic drug products and thus are ineligible for marketing without an approved application under section 505G of the FD&C Act.\n\nMagnesium-containing drug product\n\nSimilarly, although your firm does not specifically list magnesium oil as an active ingredient on the label of your “(b)(4) Magnesium Oil Spray” product, the product labeling clearly represents magnesium as an active ingredient. For instance, the label includes the statement, “[r]esearch shows magnesium can ease stress, anxiety, muscle\u002Fjoint pain, and headaches, and aid in promoting restful sleep.” Because as noted magnesium was not an active ingredient under any applicable final monograph or TFM, your \"(b)(4) Magnesium Oil Spray” product would not meet the conditions for lawful marketing without an approved application under section 505G(a)(1) or (2). This product would also be ineligible for marketing without an approved application under section 505G(a)(1) or (2) because its labeling is inconsistent with the conditions applicable to OTC external analgesics, in that the product claims regarding easing of stress and anxiety reflect indications not included under the external analgesic TFM.12\n\nIn addition to failing to meet the conditions for marketing under section 505G(a)(1) or (2) of the FD&C Act, your “(b)(4) Magnesium Oil Spray” product does not meet the other conditions under section 505G under which nonprescription drug products can be lawfully marketed without an approved application. Specifically, it does not satisfy the requirements under sections 505G(a)(3)13 nor is its marketing permitted by an order issued under section 505G(b)(1).14 Your “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products also cannot meet such other marketing conditions because they are inapplicable, given that these products are labeled as homeopathic drug products which, again, are not governed by section 505G.\n\nFor the above reasons, your “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream” and “(b)(4) Magnesium Oil Spray” products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d).\n\nSilver-containing Drug Products\n\nBased on their labeling, your products “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” and “(b)(4) Silver Liquid Supplement” are drugs that contain silver as an active ingredient. Further, these products lack an approved application and are made available for purchase by consumers without a prescription, i.e., OTC. Accordingly, these products are subject to section 505G of the FD&C Act, which as noted above governs nonprescription drugs marketed without an approved application. Specifically, your silver products fall under section 505G(a)(5) of the FD&C Act, because under a final determination issued under 21 CFR part 330, as published in the Federal Register on August 17, 1999,15 the Agency has determined that no silver containing OTC drugs are GRASE under section 201(p)(1) of the FD&C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&C Act to be lawfully marketed.16\n\nNew drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are eligible to be marketed without an approved application under section 505G of the FD&C Act, among other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your firm’s “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” drug products. Nor are these products eligible to be marketed without an approved application under section 505G of the FD&C Act. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Drugs\n\nYour “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” products are misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 502 and 301(a) of the FD&C Act, 21 U.S.C. 352 and 331(a).\n\nAs explained above, your “(b)(4) Magnesium Oil Spray,” \"(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” and “(b)(4) Silver Liquid Supplement\" products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section, and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355. Consequently, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). In addition, your silver-containing products \"(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” and “(b)(4) Silver Liquid Supplement\" are misbranded under section 502 of the FD&C Act by virtue of 21 CFR 310.548(b).17\n\nFurthermore, your “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products are also misbranded under section 502(a) of the FD&C Act because the labeling of these products is false and misleading for several reasons. First, the labeling for your “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products identifies CBD as an inactive ingredient, but represents CBD as having purported active pharmacological properties such as pain relief, among others. Even if CBD could be considered an inactive ingredient in these products, the prominent featuring of CBD on the labeling on your “(b)(4) Therapeutic Pain Gel” and “(b)(4) Pain Relief Cream” products causes the products to be misbranded under section 502(a) of the FD&C Act, which deems a drug to be misbranded if its labeling is “false or misleading in any particular,” and under 21 CFR 201.10(c)(4). Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason … [of] the featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.” Similarly, although the labeling for your \"(b)(4) Magnesium Oil Spray” product does not specifically list magnesium oil as an active ingredient, your labeling claims represent magnesium as an active ingredient, as described above, and thus this product is also misbranded under section 502(a) of the FD&C Act and 21 CFR 201.10(c)(4).\n\nAccordingly, your “(b)(4) Silver Gel,” “(b)(4) Silver Gel,” “(b)(4) Silver Gel with Aloe,” “(b)(4) Silver Liquid Supplement,” “(b)(4) Therapeutic Pain Gel,” “(b)(4) Pain Relief Cream,” and “(b)(4) Magnesium Oil Spray” products are misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 502 and 301(a) of the FD&C Act, 21 U.S.C. 352 and 331(a).\n\nMisbranded Dietary Supplements\n\nYour (b)(4) Silver Liquid Supplement (even if not considered an unapproved new drug and\u002For a misbranded drug), (b)(4) Silver, (b)(4) Silver Water, and (b)(4) Silver products are misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101, as follows:\n\n1. Your (b)(4) Silver and (b)(4) Silver Water products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. 343 (e)(1)] in that the label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\n\n2. Your (b)(4) Silver Liquid Supplement, (b)(4) Silver, (b)(4) Silver (b)(4), and (b)(4) Silver products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the products do not present nutrition information on the labeling as required by 21 CFR 101.36 and 21 CFR 101.9. For example:\n\nYour (b)(4) Silver Liquid Supplement, (b)(4) Silver, (b)(4) Silver (b)(4), and (b)(4) Silver products labels fail to list the serving sizes which include 1 teaspoon twice daily for people under 75 pounds (lbs.) and 2 teaspoons twice daily for people over 75 lbs. If the product is for persons within more than one group, the quantitative amount and percent of Daily Value for each group shall be presented in separate columns in accordance with 21 CFR 101.36(b)(2)(iii)(E)\n\n3. Your (b)(4) Silver, (b)(4) Silver (b)(4), and (b)(4) Silver products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. 343(s)(2)(B)] because the product labels do not include a statement of identity as a “dietary supplement” as required by 21 CFR 101.3(g).\n\n4. Your (b)(4) Silver and (b)(4) Silver (b)(4) products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\n\nAdditionally,\n\n1. Your (b)(4) Silver Liquid Supplement, (b)(4) Silver, (b)(4) Silver (b)(4), and (b)(4) Silver product labels bear the following statement: “DV (Daily Value) based on a 2,000 calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, added sugars, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\n\n2. Your (b)(4) Silver Liquid Supplement, (b)(4) Silver, (b)(4) Silver (b)(4), and (b)(4) Silver product labels are using an incorrect version of the FDA disclaimer. This FDA disclaimer is only required when certain statements as mentioned in 21 CFR 101.93(f) are declared on the label.\n\nCGMP consultant recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified third party perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the effectiveness of your corrective actions and preventive actions.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for fully resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAny drug marketed by your firm must conform with all applicable requirements of the FD&C Act, including those outlined in the Unapproved New Drug and Misbranding Charges section of this letter.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFailure to promptly correct any violations may result in legal action without further notice including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer. We may re-inspect to verify that you have completed your corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and your schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease submit your response via email to ORAPHARM3_RESPONSES@FDA.HHS.GOV.\n\nAttention: Brian D. Garthwaite, Ph. D.\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nIf you have any questions, please contact Dr. Garthwaite at (612) 758-7132.\n\nSincerely,\n\n\u002FS\u002F\n\nArt O. Czabaniuk\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n________________________________\n\n1 Section 505G of the FD&C Act was added under title III, subtitle F (\"Over-the-Counter Drugs\") of the CARES Act, Pub. L 116-136 (March 27, 2020).\n\n2 Your “(b)(4) Magnesium Oil Spray” is made available for purchase by consumers without a prescription.\n\n3 We note that OTC drug products intended for external analgesic indications, such as the temporary relief of pain, were addressed in the Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, magnesium was not included as an active ingredient under this TFM.\n\n4 See section 3853(a) of the CARES Act, Pub. L. 116-136 (March 27, 2020).\n\n5 See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, CBD was not included as an active ingredient under this TFM. 6 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n7 21 CFR 330.1(e) requires that \"the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity\".\n\n8 See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\n\n9 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n10 See 21 CFR 330.1(e).\n\n11 For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\n\n12 See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). As noted above, easing of stress and anxiety were not indications included under this TFM.\n\n13 Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including labeling conditions, and comply with all other applicable requirements for nonprescription drugs. Drugs containing magnesium as an active ingredient were not classified under any applicable TFM as Category III for safety or effectiveness. Thus, your “(b)(4) Magnesium Oil Spray” product does not meet the conditions under section 505G(a)(3) for lawful marketing absent an approved application.\n\n14 Your “(b)(4) Magnesium Oil Spray” product is not the subject of an order issued under section 505G(b)(1) of the FD&C Act, 21 U.S.C 355h(b)(1), under which it is considered GRASE and can be lawfully marketed without an approved application.\n\n15 See 64 FR 44653, 44658 (Aug. 17, 1999) establishing 21 CFR 310.548(a), which states in relevant part that \"…there is a lack of adequate data to establish general recognition of the safety and effectiveness of colloidal silver ingredients or silver salts for OTC use in the treatment or prevention of any disease. These ingredients and salts include, but are not limited to, silver proteins, mild silver protein, strong silver protein, silver, silver ion, silver chloride, silver cyanide, silver iodide, silver oxide, and silver phosphate\".\n\n16 Id. at 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act\".\n\n17 See 64 FR 44653, 44658 (Aug. 17, 1999), establishing 21 CFR 310.548, which at 21 CFR 310.548(b) states that \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act\" (emphasis added).","BioLyte Laboratories, LLC","biolyte-laboratories-llc-603584-03182021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolyte-laboratories-llc-603584-03182021","2026-10-26T08:08:05.034369+00:00","Warning Letter","Issued","2021-03-22","603584","Drugs","Kevin J. DeVisser","2026-08-20T03:15:53.572+00:00","UPS Next Day","2021-03-18",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":49,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1935,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-07T04:00:00Z\">04\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstpca-inc-dba-sun-ten-laboratories-645336-04072023\">STPCA Inc. dba Sun Ten Laboratories\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Tsai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>STPCA Inc. dba Sun Ten Laboratories\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9250 Jeronimo Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618-1905\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 645336\u003Cbr>\n\u003Cbr>\nDear Mr. Tsai:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility, located at 9250 Jeronimo Rd., Irvine, CA 92618, on September 19-21, 29 and October 5, 2022. In February 2023, we also reviewed your website at the Internet address https:\u002F\u002Fsunten.com\u002F. Based on inspectional findings and a review of your website, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u002FMisbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at the Internet address https:\u002F\u002Fsunten.com\u002F in February 2023, and has determined that you take orders there for the products Yi Min, Jian Shen, Yu Zhi, Xiao Yan, Qu Yu, Yi Jun, Platcladus Leaves Ce Bai Ye, and Shu Jin 2. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Yi Min\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Relief of allergy related symptoms”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Jian Shen\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Improve… low blood sugars”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Yu Zhi\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Relief of hemorrhoids conditions and constipation”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Xiao Yan\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Reduce urinary tract infections symptoms”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Qu Yu\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Support trauma injury relief”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Yi Jun\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Relief of inflammation and fungal infection”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Platcladus Leaves Ce Bai Ye\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Aids in stopping bleeding”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Shu Jin 2\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Relief of pain and stiffness in the lower body”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Jian Shen, Xiao Yan, and Platcladus Leaves Ce Bai Ye are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Jian Shen, Xiao Yan, and Platcladus Leaves Ce Bai Ye fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The facility inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on these violations, your Lycium Formula Huan Shao Dan, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish a specification for every point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish an identity specification for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1). For example, the identification specification for the Lycium Formula (Huan Shao Dan) dietary ingredient for your Lycium Formula Huan Shao Dan finished product lists a specification as “Positive” and a testing result of “Confirm.” The Material Test Report related to this dietary ingredient has a differing specification of “Positive (Match with \u003Cstrong>(b)(4)\u003C\u002Fstrong> Standard)” and a result stated as “conforms” for Lycium Formula (Huan Shao Dan), lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. “Positive” and “Positive (Match with \u003Cstrong>(b)(4)\u003C\u002Fstrong> Standard)” do not provide specific ranges or parameters regarding the testing method used to determine if a dietary ingredient has been appropriately identified. In addition, a testing report should show various bands relating to the components of the blend or the dominant constituents of each ingredient for this type of multi-ingredient product;\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications that are necessary to ensure that the specifications for purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, you did not have specifications for the ingredients Fructus Foeniculi and Radix Rehmanniae praeparata to ensure the purity, strength, and composition specifications will be met for the Lycium Formula Huan Shao Dan finished product; and\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish specifications for identity, purity, strength, and composition for your Lycium Formula Huan Shao Dan finished product.\u003C\u002Fp>\n\n\u003Cp>Once you have established specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c). You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>In addition, under 21 CFR 111.75(a)(2), you must either conduct appropriate tests or examinations or rely on a certificate of analysis (COA) from the supplier of the component that you receive, provided that the COA meets specific requirements. To the extent you receive dietary ingredients from suppliers from which you receive a COA, you may only rely on a COA if the following conditions are met: (A) you first qualify the supplier by establishing the reliability of the supplier's COA through confirmation of the results of the supplier's tests or examinations; (B) the COA includes a description of the test or examination method(s) used, limits of the test or examinations, and actual results of the tests or examinations; (C) you maintain documentation of how you qualified the supplier; (D) you periodically reconfirm the supplier's COA; and (E) your quality control personnel review and approve the documentation setting forth the basis for qualification (and re‐qualification) of any supplier.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated October 20, 2022, and November 7, 2022. Your October 2022 response included a revised identification specification for the Lycium Formula (Huan Shao Dan) dietary ingredient. This revised specification continues to have “Confirm” as the testing result and does not provide any quantitative data to determine the ingredient’s identity has been confirmed.\u003C\u002Fp>\n\n\u003Cp>The component specification sheets provided in your October 2022 response include an identity specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (components of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product) listing a retention value (Rf value) via \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for each dietary ingredient. The Rf values identified in your Raw Material Specification sheets differ from the Rf values identified in the ingredient supplier’s Certificate of Analysis for each ingredient. Your component specification sheets document that the identity test is conducted via an in-house \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;method. You did not provide documentation to support the identity specification documented via your in-house \u003Cstrong>(b)(4)\u003C\u002Fstrong> method. In addition, and as noted above, because the product is multi-ingredient product, we would expect the finished testing specifications to include multiple bands for each of the components that would give the respective Rf values.\u003C\u002Fp>\n\n\u003Cp>Your October 2022 response also included a revised finished product specification for your Lycium Formula Huan Shao Dan finished product. The identity specification for this product also only contains the test result of “Confirmed” and no quantitative data.\u003C\u002Fp>\n\n\u003Cp>Your responses did not include any information regarding purity, strength, composition specifications related to the ingredients referenced above or to the finished product. You must establish component specifications that are necessary to ensure that specifications for the purity, strength and composition of dietary supplements manufactured using the components are met.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the component specification sheets in your October 2022 response document \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis and Fournier Transform Infrared Spectroscopy (FT-IR) analysis will be conducted against an “in-house reference standard which is established by outsourcing testing Labs.” You do not have an adequate identity specification because you are not conducting identity testing against a qualified reference standard. You did not provide procedures for creating a qualified reference standard. You did not provide documentation that you are creating a reference standard by obtaining reference standard material of highest purity by reasonable effort and thoroughly characterizing the material to ensure identity, purity, quality, and strength. You did not provide qualification documentation for these standards showing they have been reviewed and approved by quality control personnel prior to use.\u003C\u002Fp>\n\n\u003Cp>2. Your quality control personnel failed to reject a component or dietary supplement when a specification established in accordance with 21 CFR 111.70 was not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 111.113(b)(2). Your firm’s quality control personnel also failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1). For example, your finished product testing result found \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002Fserving of zinc in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which exceeded your established finished product specification for zinc at \u003Cstrong>(b)(4)\u003C\u002Fstrong> (per serving or capsule). Your quality control unit did not conduct a material review and make a disposition decision that the specification was not met.\u003C\u002Fp>\n\n\u003Cp>In addition, your quality control unit released the product \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on June 28, 2022, but third-party laboratory results for microbial testing and zinc potency were not released until July 5, 2022, and July 7, 2022, respectively.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated October 20, 2022, and November 7, 2022. Your October 2022 response stated that you have trained personnel on conducting investigations when specifications are not met. Your response did not describe the type of training provided or include evidence of training records demonstrating the associated personnel will be able to release components and finished products appropriately.\u003C\u002Fp>\n\n\u003Cp>Your November 2022 response included an OOS [out-of-specification] Investigation Report regarding the zinc levels in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As part of this investigation, it appears that a reserve sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was tested and found to have a level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per capsule, which would have been within the specification. However, the investigation testing was performed using a different methodology and by a different laboratory than the laboratory which conducted the original analysis, thus making it difficult to compare the results and to verify accuracy.\u003C\u002Fp>\n\n\u003Cp>3. You failed to establish master manufacturing records (MMRs) that include all required components of 21 CFR 111.210. Specifically, the MMRs for your Lycium Formula Huan Shao Dan, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> products failed to include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The MMRs for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> product failed to include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete list of components to be used [21 CFR 111.210(b)];\u003C\u002Fli>\n\t\u003Cli>An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\u003C\u002Fli>\n\t\u003Cli>The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)]; • A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\u003C\u002Fli>\n\t\u003Cli>A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\u003C\u002Fli>\n\t\u003Cli>Written instructions [21 CFR 111.210(h)], including the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; o Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packed and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(1)].\u003Cbr>\n&nbsp; &nbsp; &nbsp; o Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\u003Cbr>\n&nbsp; &nbsp; &nbsp; o Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; i. Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; ii. For manual operations, such specific actions must include [21 CFR 111.210(h)(3)(ii)]:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; A. One person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; B. One person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)].\u003Cbr>\n&nbsp; &nbsp; o Special notations and precautions to be followed;\u003Cbr>\n&nbsp; &nbsp; o Corrective action plans for use when a specification is not met\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, the Lycium Formula Huan Shao Dan, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. The Lycium Formula Huan Shao Dan product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. § 343 (f)] because the product label’s front panel and dietary ingredients listed in the proprietary blend contain information in two languages but do not repeat all the required label information (including the nutrition information) in both languages. In accordance with 21 CFR 101.15(c), if a product label contains any representation in a foreign language or foreign characters, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language.\u003C\u002Fp>\n\n\u003Cp>2. The Lycium Formula Huan Shao Dan product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343 (s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\u003C\u002Fp>\n\n\u003Cp>3. The Lycium Formula Huan Shao Dan, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual name (standardized common name) or Latin binomial of each ingredient (in the absence of a standardized common name per \u003Cstrong>Herbs of Commerce\u003C\u002Fstrong>) used as required by 21 CFR 101.4(h).\u003C\u002Fp>\n\n\u003Cp>4. The Lycium Formula Huan Shao Dan and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded within the meaning of section 403(q)(5)(F) the Act [21 U.S.C § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of the products does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your Lycium Formula Huan Shao fails to place the heading, “Amount Per Serving,” above the listed quantitative amount per serving in accordance with 21 CFR 101.36(e)(1).\u003C\u002Fp>\n\n\u003Cp>b. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Zinc \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes a footnote to the % Daily Value for zinc that specifies Recommended Daily Allowances for zinc that vary depending on different groups or persons. There is no provision in the regulation for a symbol that links to the same symbol appearing before information concerning Recommended Daily Allowances for different groups or persons. Furthermore, this Recommended Daily Allowance statement represents that this product is intended for different groups of persons. The product’s Supplement Facts label fails to list the serving size for each of the groups indicated on the label. If the product is represented for persons within more than one group, the quantitative amount and percent of Daily Value for each group shall be presented in separate columns in accordance with 21 CFR 101.36(b)(2)(iii)(E).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild Irvine, CA 9261\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS# 645336 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov or 510-337-6854.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Tsai\n\nRecipient Title\n\nCOO\n\nSTPCA Inc. dba Sun Ten Laboratories\n\n9250 Jeronimo Rd.\n\nIrvine, CA 92618-1905\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nCMS # 645336\n\nDear Mr. Tsai:\n\nThe U.S. Food and Drug Administration (FDA) inspected your facility, located at 9250 Jeronimo Rd., Irvine, CA 92618, on September 19-21, 29 and October 5, 2022. In February 2023, we also reviewed your website at the Internet address https:\u002F\u002Fsunten.com\u002F. Based on inspectional findings and a review of your website, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nUnapproved New Drugs\u002FMisbranded Drugs\n\nFDA reviewed your website at the Internet address https:\u002F\u002Fsunten.com\u002F in February 2023, and has determined that you take orders there for the products Yi Min, Jian Shen, Yu Zhi, Xiao Yan, Qu Yu, Yi Jun, Platcladus Leaves Ce Bai Ye, and Shu Jin 2. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nYi Min\n\n“Relief of allergy related symptoms”\n\nJian Shen\n\n“Improve… low blood sugars”\n\nYu Zhi\n\n“Relief of hemorrhoids conditions and constipation”\n\nXiao Yan\n\n“Reduce urinary tract infections symptoms”\n\nQu Yu\n\n“Support trauma injury relief”\n\nYi Jun\n\n“Relief of inflammation and fungal infection”\n\nPlatcladus Leaves Ce Bai Ye\n\n“Aids in stopping bleeding”\n\nShu Jin 2\n\n“Relief of pain and stiffness in the lower body”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Jian Shen, Xiao Yan, and Platcladus Leaves Ce Bai Ye are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Jian Shen, Xiao Yan, and Platcladus Leaves Ce Bai Ye fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe facility inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on these violations, your Lycium Formula Huan Shao Dan, (b)(4) Zinc (b)(4), and (b)(4) products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of CGMP requirements are as follows:\n\n1. Your firm failed to establish a specification for every point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). Specifically:\n\na. You failed to establish an identity specification for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1). For example, the identification specification for the Lycium Formula (Huan Shao Dan) dietary ingredient for your Lycium Formula Huan Shao Dan finished product lists a specification as “Positive” and a testing result of “Confirm.” The Material Test Report related to this dietary ingredient has a differing specification of “Positive (Match with (b)(4) Standard)” and a result stated as “conforms” for Lycium Formula (Huan Shao Dan), lot number (b)(4). “Positive” and “Positive (Match with (b)(4) Standard)” do not provide specific ranges or parameters regarding the testing method used to determine if a dietary ingredient has been appropriately identified. In addition, a testing report should show various bands relating to the components of the blend or the dominant constituents of each ingredient for this type of multi-ingredient product;\n\nb. You failed to establish specifications that are necessary to ensure that the specifications for purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, you did not have specifications for the ingredients Fructus Foeniculi and Radix Rehmanniae praeparata to ensure the purity, strength, and composition specifications will be met for the Lycium Formula Huan Shao Dan finished product; and\n\nc. You failed to establish specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish specifications for identity, purity, strength, and composition for your Lycium Formula Huan Shao Dan finished product.\n\nOnce you have established specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c). You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\nIn addition, under 21 CFR 111.75(a)(2), you must either conduct appropriate tests or examinations or rely on a certificate of analysis (COA) from the supplier of the component that you receive, provided that the COA meets specific requirements. To the extent you receive dietary ingredients from suppliers from which you receive a COA, you may only rely on a COA if the following conditions are met: (A) you first qualify the supplier by establishing the reliability of the supplier's COA through confirmation of the results of the supplier's tests or examinations; (B) the COA includes a description of the test or examination method(s) used, limits of the test or examinations, and actual results of the tests or examinations; (C) you maintain documentation of how you qualified the supplier; (D) you periodically reconfirm the supplier's COA; and (E) your quality control personnel review and approve the documentation setting forth the basis for qualification (and re‐qualification) of any supplier.\n\nWe have reviewed your responses, dated October 20, 2022, and November 7, 2022. Your October 2022 response included a revised identification specification for the Lycium Formula (Huan Shao Dan) dietary ingredient. This revised specification continues to have “Confirm” as the testing result and does not provide any quantitative data to determine the ingredient’s identity has been confirmed.\n\nThe component specification sheets provided in your October 2022 response include an identity specification for (b)(4), and (b)(4) (components of your (b)(4) product) listing a retention value (Rf value) via (b)(4) analysis for each dietary ingredient. The Rf values identified in your Raw Material Specification sheets differ from the Rf values identified in the ingredient supplier’s Certificate of Analysis for each ingredient. Your component specification sheets document that the identity test is conducted via an in-house (b)(4) method. You did not provide documentation to support the identity specification documented via your in-house (b)(4) method. In addition, and as noted above, because the product is multi-ingredient product, we would expect the finished testing specifications to include multiple bands for each of the components that would give the respective Rf values.\n\nYour October 2022 response also included a revised finished product specification for your Lycium Formula Huan Shao Dan finished product. The identity specification for this product also only contains the test result of “Confirmed” and no quantitative data.\n\nYour responses did not include any information regarding purity, strength, composition specifications related to the ingredients referenced above or to the finished product. You must establish component specifications that are necessary to ensure that specifications for the purity, strength and composition of dietary supplements manufactured using the components are met.\n\nFurthermore, the component specification sheets in your October 2022 response document (b)(4) analysis and Fournier Transform Infrared Spectroscopy (FT-IR) analysis will be conducted against an “in-house reference standard which is established by outsourcing testing Labs.” You do not have an adequate identity specification because you are not conducting identity testing against a qualified reference standard. You did not provide procedures for creating a qualified reference standard. You did not provide documentation that you are creating a reference standard by obtaining reference standard material of highest purity by reasonable effort and thoroughly characterizing the material to ensure identity, purity, quality, and strength. You did not provide qualification documentation for these standards showing they have been reviewed and approved by quality control personnel prior to use.\n\n2. Your quality control personnel failed to reject a component or dietary supplement when a specification established in accordance with 21 CFR 111.70 was not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 111.113(b)(2). Your firm’s quality control personnel also failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1). For example, your finished product testing result found (b)(4)\u002Fserving of zinc in your (b)(4) Zinc (b)(4) product, lot number (b)(4), which exceeded your established finished product specification for zinc at (b)(4) (per serving or capsule). Your quality control unit did not conduct a material review and make a disposition decision that the specification was not met.\n\nIn addition, your quality control unit released the product (b)(4) Zinc (b)(4), lot number (b)(4), on June 28, 2022, but third-party laboratory results for microbial testing and zinc potency were not released until July 5, 2022, and July 7, 2022, respectively.\n\nWe have reviewed your responses, dated October 20, 2022, and November 7, 2022. Your October 2022 response stated that you have trained personnel on conducting investigations when specifications are not met. Your response did not describe the type of training provided or include evidence of training records demonstrating the associated personnel will be able to release components and finished products appropriately.\n\nYour November 2022 response included an OOS [out-of-specification] Investigation Report regarding the zinc levels in (b)(4) Zinc (b)(4), lot number (b)(4). As part of this investigation, it appears that a reserve sample of (b)(4) Zinc (b)(4), lot number (b)(4), was tested and found to have a level of (b)(4) per capsule, which would have been within the specification. However, the investigation testing was performed using a different methodology and by a different laboratory than the laboratory which conducted the original analysis, thus making it difficult to compare the results and to verify accuracy.\n\n3. You failed to establish master manufacturing records (MMRs) that include all required components of 21 CFR 111.210. Specifically, the MMRs for your Lycium Formula Huan Shao Dan, (b)(4), and (b)(4) Zinc (b)(4) products failed to include:\n\nA description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\n\nThe MMRs for your (b)(4) Zinc (b)(4) product failed to include:\n\nA complete list of components to be used [21 CFR 111.210(b)];\n\nAn accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\n\nThe identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)]; • A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\n\nA statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\n\nWritten instructions [21 CFR 111.210(h)], including the following:\n\no Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packed and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(1)].\n\no Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\n\no Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\n\ni. Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\n\nii. For manual operations, such specific actions must include [21 CFR 111.210(h)(3)(ii)]:\n\nA. One person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\n\nB. One person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)].\n\no Special notations and precautions to be followed;\n\no Corrective action plans for use when a specification is not met\n\nMisbranded Dietary Supplements\n\nIn addition, the Lycium Formula Huan Shao Dan, (b)(4), and (b)(4) Zinc (b)(4) products are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. The Lycium Formula Huan Shao Dan product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. § 343 (f)] because the product label’s front panel and dietary ingredients listed in the proprietary blend contain information in two languages but do not repeat all the required label information (including the nutrition information) in both languages. In accordance with 21 CFR 101.15(c), if a product label contains any representation in a foreign language or foreign characters, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language.\n\n2. The Lycium Formula Huan Shao Dan product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343 (s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\n\n3. The Lycium Formula Huan Shao Dan, (b)(4), and (b)(4) products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual name (standardized common name) or Latin binomial of each ingredient (in the absence of a standardized common name per Herbs of Commerce) used as required by 21 CFR 101.4(h).\n\n4. The Lycium Formula Huan Shao Dan and (b)(4) Zinc (b)(4) products are misbranded within the meaning of section 403(q)(5)(F) the Act [21 U.S.C § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of the products does not comply with 21 CFR 101.36. For example:\n\na. Your Lycium Formula Huan Shao fails to place the heading, “Amount Per Serving,” above the listed quantitative amount per serving in accordance with 21 CFR 101.36(e)(1).\n\nb. Your (b)(4) Zinc (b)(4) includes a footnote to the % Daily Value for zinc that specifies Recommended Daily Allowances for zinc that vary depending on different groups or persons. There is no provision in the regulation for a symbol that links to the same symbol appearing before information concerning Recommended Daily Allowances for different groups or persons. Furthermore, this Recommended Daily Allowance statement represents that this product is intended for different groups of persons. The product’s Supplement Facts label fails to list the serving size for each of the groups indicated on the label. If the product is represented for persons within more than one group, the quantitative amount and percent of Daily Value for each group shall be presented in separate columns in accordance with 21 CFR 101.36(b)(2)(iii)(E).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild Irvine, CA 9261\n\nRefer to Unique Identification Number CMS# 645336 when replying.\n\nIf you have any questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov or 510-337-6854.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","STPCA Inc. dba Sun Ten Laboratories","stpca-inc-dba-sun-ten-laboratories-645336-04072023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstpca-inc-dba-sun-ten-laboratories-645336-04072023","2026-10-26T08:10:06.34827+00:00","2023-08-15","645336","DrugsFood & Beverages","Division of Human and Animal Food Operations West V","Mr. Michael Tsai","2026-08-20T00:47:57.302+00:00","United Parcel Service","2023-04-07",{"id":55,"raw":56,"subject":12,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2813,[57,58,59,60,12,13,13,13],"\u003Ctime datetime=\"2022-03-15T13:20:00Z\">03\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-24T05:00:00Z\">02\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faccu-bio-chem-laboratories-619450-02242022\">Accu Bio-Chem Laboratories\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vano Baghdasarian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Lab Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Accu Bio-Chem Laboratories\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1755 Victory Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Glendale\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91201-2864\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 24, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Baghdasarian:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Accu Bio-Chem Laboratories, FEI 3004876794, at 1755 Victory Blvd, Glendale, California from August 24 to 31, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 12, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not adequately investigate out-of-specification (OOS) results. Specifically, you prepared a new test preparation of the original sample for multiple over-the-counter (OTC) drug products with OOS results for assay. Your practice of preparing and testing new samples of OTC drug products to confirm the original test results without first adequately investigating the initial failing result is not scientifically justified. Also, your procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Out of Specification Investigation, lacks appropriate instructions to determine the root cause of the OOS results. Your procedure allows laboratory personnel \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There is no scientific justification \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you updated your standard operating procedure for OOS investigations to include directions to perform a retest of the original sample to confirm the original result. You also stated that your OOS investigations always included \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not included in your OOS investigation reports. Further, you stated that you have updated your OOS procedure and OOS investigation report to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide a retrospective review of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that you have fully identified and thoroughly investigated all OOS results. Your revised OOS procedure remains unchanged regarding when an OOS result can be invalidated. In addition, neither your current OOS procedure nor your OOS investigation report assessment at the time of inspection \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the original sample preparation \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS (including release and stability testing) results for drug product testing conducted for the last three years and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>\no Determine whether the scientific justification and evidence relating to all invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include notifications sent to the client.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive review and remediation plan for your OOS result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\u003Cbr>\no Quality unit oversight of laboratory investigations\u003Cbr>\no Identification of adverse laboratory control trends\u003Cbr>\no Resolution of causes of laboratory variation\u003Cbr>\no Adequately scoping of each investigation and its CAPA\u003Cbr>\no Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform method verification to ensure that the chemical and microbiological test methods used to analyze OTC drug products were suitable for their intended use. For example, you used the same assay test method for the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> in different drug products of varying formulations. You also tested various drug products for the presence of microorganisms using compendial test methods without verifying the suitability of the methods for each drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You have not provided assurance that the data you generated from your testing methods is accurate. The timeframe you have given to complete method verification studies is not appropriate.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent assessment of your chemical and microbiological drug test methods to determine the suitability of the method (i.e., method verification or method validation when performing analysis for clients). If verification or validation is needed, provide a plan and timeline for completion of the appropriate activity and commitment that you will notify your clients of the outcome.\u003C\u002Fp>\n\n\u003Cp>• Updated procedures documenting how the suitability of all testing methods will be determined, when method verification and validation occur, and corresponding training records.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The electronic data systems that you use to generate drug product results lack appropriate controls. There is no assurance that your systems have the appropriate controls to prevent deletion of data and record all modifications to data. For example, electronic data files generated from your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;system, used for identity testing of drug products, could be deleted. In addition, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> that controls your high-performance liquid chromatography and gas chromatography systems for testing the actives in OTC drug products did not have all appropriate audit trails enabled to record significant changes.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have contacted the equipment and software manufacturers with requests for guidance on implementing the necessary controls to prevent data deletion. Your response is inadequate because you did not provide an assessment of your data systems to determine what data was deleted and its impact on the drug products that you test. In addition, you failed to have adequate interim measures in place while you apply updates for your software systems.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems (paper and electronic) used throughout your laboratory testing operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>• Your action plan with timelines to enable audit trails for all applicable electronic laboratory data systems. Also describe your interim controls and specify when procedures will be implemented for the review of all audit trails.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibility of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients.\u003C\u002Fp>\n\n\u003Cp>It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any out-of-specification results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 619450.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Bryan Galvez, Acting Compliance Officer via email at, Bryan.Galvez@fda.hhs.gov or by telephone at 949-608-2960.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lance M. De Souza\u003Cbr>\nActing Director, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vano Baghdasarian\n\nRecipient Title\n\nLab Director\n\nAccu Bio-Chem Laboratories\n\n1755 Victory Blvd\n\nGlendale, CA 91201-2864\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nFebruary 24, 2022\n\nDear Mr. Baghdasarian:\n\nThe U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Accu Bio-Chem Laboratories, FEI 3004876794, at 1755 Victory Blvd, Glendale, California from August 24 to 31, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 12, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following:\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm did not adequately investigate out-of-specification (OOS) results. Specifically, you prepared a new test preparation of the original sample for multiple over-the-counter (OTC) drug products with OOS results for assay. Your practice of preparing and testing new samples of OTC drug products to confirm the original test results without first adequately investigating the initial failing result is not scientifically justified. Also, your procedure, (b)(4) Out of Specification Investigation, lacks appropriate instructions to determine the root cause of the OOS results. Your procedure allows laboratory personnel (b)(4). There is no scientific justification (b)(4).\n\nIn your response, you stated that you updated your standard operating procedure for OOS investigations to include directions to perform a retest of the original sample to confirm the original result. You also stated that your OOS investigations always included (b)(4); however, (b)(4) were not included in your OOS investigation reports. Further, you stated that you have updated your OOS procedure and OOS investigation report to include (b)(4).\n\nYour response is inadequate because you did not provide a retrospective review of (b)(4) to ensure that you have fully identified and thoroughly investigated all OOS results. Your revised OOS procedure remains unchanged regarding when an OOS result can be invalidated. In addition, neither your current OOS procedure nor your OOS investigation report assessment at the time of inspection (b)(4) of the original sample preparation (b)(4).\n\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-test-results-pharmaceutical-production.\n\nIn response to this letter, provide the following:\n\n• A retrospective, independent review of all invalidated OOS (including release and stability testing) results for drug product testing conducted for the last three years and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to all invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include notifications sent to the client.\n\n• A comprehensive review and remediation plan for your OOS result investigation systems. The corrective action and preventive action (CAPA) should include, but not be limited to, addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\n2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou failed to perform method verification to ensure that the chemical and microbiological test methods used to analyze OTC drug products were suitable for their intended use. For example, you used the same assay test method for the active ingredient (b)(4) in different drug products of varying formulations. You also tested various drug products for the presence of microorganisms using compendial test methods without verifying the suitability of the methods for each drug product.\n\nYour response is inadequate. You have not provided assurance that the data you generated from your testing methods is accurate. The timeframe you have given to complete method verification studies is not appropriate.\n\nIn response to this letter, provide the following:\n\n• A comprehensive independent assessment of your chemical and microbiological drug test methods to determine the suitability of the method (i.e., method verification or method validation when performing analysis for clients). If verification or validation is needed, provide a plan and timeline for completion of the appropriate activity and commitment that you will notify your clients of the outcome.\n\n• Updated procedures documenting how the suitability of all testing methods will be determined, when method verification and validation occur, and corresponding training records.\n\n3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nThe electronic data systems that you use to generate drug product results lack appropriate controls. There is no assurance that your systems have the appropriate controls to prevent deletion of data and record all modifications to data. For example, electronic data files generated from your (b)(4) system, used for identity testing of drug products, could be deleted. In addition, the (b)(4) that controls your high-performance liquid chromatography and gas chromatography systems for testing the actives in OTC drug products did not have all appropriate audit trails enabled to record significant changes.\n\nIn your response, you stated that you have contacted the equipment and software manufacturers with requests for guidance on implementing the necessary controls to prevent data deletion. Your response is inadequate because you did not provide an assessment of your data systems to determine what data was deleted and its impact on the drug products that you test. In addition, you failed to have adequate interim measures in place while you apply updates for your software systems.\n\nIn response to this letter, provide the following:\n\n• A complete assessment of documentation systems (paper and electronic) used throughout your laboratory testing operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• Your action plan with timelines to enable audit trails for all applicable electronic laboratory data systems. Also describe your interim controls and specify when procedures will be implemented for the review of all audit trails.\n\nResponsibility of a Contract Testing Lab\n\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients.\n\nIt is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any out-of-specification results or significant problems encountered during the testing of these drugs.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 619450.\n\nIf you have questions regarding the contents of this letter, please contact Bryan Galvez, Acting Compliance Officer via email at, Bryan.Galvez@fda.hhs.gov or by telephone at 949-608-2960.\n\nSincerely,\n\n\u002FS\u002F\n\nLance M. De Souza\n\nActing Director, Division of Pharmaceutical Quality Operations IV","Accu Bio-Chem Laboratories","accu-bio-chem-laboratories-619450-02242022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faccu-bio-chem-laboratories-619450-02242022","2026-10-26T08:07:49.455001+00:00","2022-03-15","619450","Mr. Vano Baghdasarian","2026-08-20T02:05:45.478+00:00","VIA UPS","2022-02-24",{"id":75,"raw":76,"subject":12,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":90,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},2093,[77,78,79,80,12,13,13,13],"\u003Ctime datetime=\"2023-05-23T13:20:00Z\">05\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-24T04:00:00Z\">03\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsure-biochem-laboratories-llc-646619-03242023\">Sure-Biochem Laboratories, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tiffany Heigler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sure-Biochem Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1000 Atlantic Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Camden\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter #646619\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 24, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Heigler:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Sure-Biochem Laboratories, LLC, FEI 3023533273, at 1000 Atlantic Ave., Camden, NJ, from September 28 to October 7, 2022. Our inspection determined that you are a contract testing laboratory conducting microbial testing including, but not limited to, finished drugs.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drugs you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to follow required laboratory control mechanisms and to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(a) and 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately establish and follow procedures for growth promotion testing of your microbiological media to assure suitability before use, including failing to establish appropriate challenge conditions and acceptance criteria to ensure the media could support appropriate growth. For example, your growth promotion testing conducted on July 13, 2022, for \u003Cem>Salmonella\u003C\u002Fem> media lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified light and moderate growth for the challenge organisms including \u003Cem>Escherichia coli\u003C\u002Fem>. You accepted the lot for use without noting the deviation as required by your established procedure that specifies the growth of \u003Cem>Escherichia coli\u003C\u002Fem> should be inhibited. Further, you also failed to conduct growth promotion for each lot of media received.\u003C\u002Fp>\n\n\u003Cp>Additionally, you did not validate your alternative microbial methods used to test drug products to assure the methods were equivalent to or better than USP methods. Specifically, you failed to adequately establish that your microbiological testing methods can reliably detect objectionable microorganisms. For example, Lab Numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were samples of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products marketed for pre- and post-surgical oral care and intended for use with patients who are particularly susceptible to infection.\u003C\u002Fp>\n\n\u003Cp>Your microbial method failed to detect \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> (\u003Cem>Bcc\u003C\u002Fem>), and you reported “Not Detected” to your client. Subsequently, you sent microbial subcultures from these samples to another external laboratory that detected \u003Cem>Burkholderia contaminans\u003C\u002Fem> in both samples, a species that is part of \u003Cem>Bcc\u003C\u002Fem>. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product to be tested must be established and validated.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to performing growth promotion for every lot of purchased media and revising your growth promotion procedure to ensure media can support acceptable growth. You also acknowledge that your alternative method used to test drug products was insufficient to detect \u003Cem>Bcc\u003C\u002Fem>, and state that you will develop a procedure for the USP &lt;60&gt; test method. However, your response is inadequate because it does not address how you will review the validity of previous results using your alternative methods, or how you will communicate with your clients about these potentially noncompliant analyses. You also state that you will perform method suitability verifications for each type of product, but do not detail the actions you would take if suitability verifications are found inadequate.\u003C\u002Fp>\n\n\u003Cp>Your clients rely on your laboratory data for critical information about the quality of their drugs. Thus, it is important that your test methods are properly verified or validated, and that you use appropriate test methods to enable your clients to make proper decisions (e.g., lot disposition). Results generated using unverified or unvalidated methods can mislead customers and may put consumers at risk.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A retrospective assessment of prior testing to assure 'suitability' of your methods for the last \u003Cstrong>(b)(4)\u003C\u002Fstrong> years of testing, and a commitment to notify customers of any deficiencies. Include any revised testing results provided to your clients with incorrect enumeration calculations.\u003C\u002Fli>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data, records, and reporting, including results of the data review for drugs tested. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A procedure to establish a quantitative, acceptance criteria rather than qualitative growth entries (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) included in your growth promotion testing.\u003C\u002Fli>\n\t\u003Cli>Raw data from inoculation studies of your drugs to ensure appropriate identification of objectionable microorganisms including, but not limited to \u003Cem>Bcc\u003C\u002Fem>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) lacked adequate control over your testing operations and failed to ensure that you had suitable procedures. For example, your QU failed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>To adequately retain documentation for the review, approval, or rejection, of laboratory testing materials such as buffers, reagents, and media. There is a lack of assurance that testing materials used to conduct microbial testing meet all appropriate specifications before use of an incoming lot, and include evaluation of certificates of analysis (COA).\u003C\u002Fli>\n\t\u003Cli>To ensure procedures were followed to document and retain records such as laboratory investigations, corrective action and preventive action plans (CAPA), and change controls. You told our investigators that you were not following a number of your standard operating procedures (SOPs).\u003C\u002Fli>\n\t\u003Cli>To establish an adequate CGMP training program. You lacked appropriate resources to perform QU related functions and our inspection revealed basic CGMP violations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you admit to not adhering to your SOPs and state that you will document receipt of all incoming testing materials and retain the associated documentation. You also committed to hiring a quality consultant to develop a CGMP training program and perform quality functions. However, your response is inadequate because you did not commit to conducting a retrospective review to ensure materials used for drug product testing were suitable for their intended use. In addition, you state that your lab technician will attend “21 CFR 820 training,” which is applicable to medical devices, but does not address the lack of CGMP training for drugs.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf .\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective review of records for testing using received materials to assure correct materials were used and acceptable.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each lot and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent summary of your retrospective review of records for \u003Cstrong>(b)(4)\u003C\u002Fstrong> years of testing using received materials to assure correct materials were used and acceptable.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your laboratory records do not include complete testing data to support the analysis performed. For example, your records lack a statement of methods used for testing, a statement of the results of tests and how they compare to the established specifications, a record of all critical equipment used, and confirmation of compliance with testing conditions. Furthermore, you were unable to provide raw data to support the suitability of your alternative methods for each drug tested.\u003C\u002Fp>\n\n\u003Cp>All CGMP-related data must be retained by all laboratories, including contract testing laboratories, to enable appropriate assessments and decisions by the QU and customers, and to demonstrate ongoing control.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you will revise your records to include the missing information. Your response is inadequate because you make no commitment to retrospectively review prior testing for completeness, validity, or for errors.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent assessment of documentation practices used throughout your laboratory operations to determine where documentation is insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An independent assessment that summarizes the potential impact on product quality of the inadequate documentation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP when performing analytical work for your customers. Your laboratory role is critical to the pharmaceutical supply chain, and it is essential that you meet all CGMPs related to your function. As part of this responsibility, it is essential that you provide prompt, complete, and transparent analytical information to your customers (e.g., manufacturers) to enable them to handle their quality responsibilities related to batch evaluation and contractor oversight. This responsibility includes, but is not limited to, conveying to the customer any out-of-specification (OOS) investigations performed by your firm.\u003C\u002Fp>\n\n\u003Cp>For additional information refer to \u003Cem>FDA Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant (i.e., an independent third party) qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Identify your response with FEI# 3023533273.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nTiffany Heigler\n\nRecipient Title\n\nPresident and CEO\n\nSure-Biochem Laboratories, LLC\n\n1000 Atlantic Ave\n\nCamden, NJ 08104\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter #646619\n\nMarch 24, 2023\n\nDear Ms. Heigler:\n\nThe U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Sure-Biochem Laboratories, LLC, FEI 3023533273, at 1000 Atlantic Ave., Camden, NJ, from September 28 to October 7, 2022. Our inspection determined that you are a contract testing laboratory conducting microbial testing including, but not limited to, finished drugs.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drugs you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to follow required laboratory control mechanisms and to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(a) and 211.160(b)).\n\nYou failed to adequately establish and follow procedures for growth promotion testing of your microbiological media to assure suitability before use, including failing to establish appropriate challenge conditions and acceptance criteria to ensure the media could support appropriate growth. For example, your growth promotion testing conducted on July 13, 2022, for Salmonella media lot number (b)(4), identified light and moderate growth for the challenge organisms including Escherichia coli. You accepted the lot for use without noting the deviation as required by your established procedure that specifies the growth of Escherichia coli should be inhibited. Further, you also failed to conduct growth promotion for each lot of media received.\n\nAdditionally, you did not validate your alternative microbial methods used to test drug products to assure the methods were equivalent to or better than USP methods. Specifically, you failed to adequately establish that your microbiological testing methods can reliably detect objectionable microorganisms. For example, Lab Numbers (b)(4) and (b)(4) were samples of (b)(4) drug products marketed for pre- and post-surgical oral care and intended for use with patients who are particularly susceptible to infection.\n\nYour microbial method failed to detect Burkholderia cepacia complex (Bcc), and you reported “Not Detected” to your client. Subsequently, you sent microbial subcultures from these samples to another external laboratory that detected Burkholderia contaminans in both samples, a species that is part of Bcc. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product to be tested must be established and validated.\n\nIn your response, you commit to performing growth promotion for every lot of purchased media and revising your growth promotion procedure to ensure media can support acceptable growth. You also acknowledge that your alternative method used to test drug products was insufficient to detect Bcc, and state that you will develop a procedure for the USP \u003C60> test method. However, your response is inadequate because it does not address how you will review the validity of previous results using your alternative methods, or how you will communicate with your clients about these potentially noncompliant analyses. You also state that you will perform method suitability verifications for each type of product, but do not detail the actions you would take if suitability verifications are found inadequate.\n\nYour clients rely on your laboratory data for critical information about the quality of their drugs. Thus, it is important that your test methods are properly verified or validated, and that you use appropriate test methods to enable your clients to make proper decisions (e.g., lot disposition). Results generated using unverified or unvalidated methods can mislead customers and may put consumers at risk.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA retrospective assessment of prior testing to assure 'suitability' of your methods for the last (b)(4) years of testing, and a commitment to notify customers of any deficiencies. Include any revised testing results provided to your clients with incorrect enumeration calculations.\n\nA comprehensive investigation into the extent of the inaccuracies in data, records, and reporting, including results of the data review for drugs tested. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA procedure to establish a quantitative, acceptance criteria rather than qualitative growth entries (e.g., (b)(4)) included in your growth promotion testing.\n\nRaw data from inoculation studies of your drugs to ensure appropriate identification of objectionable microorganisms including, but not limited to Bcc.\n\n2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\n\nYour quality unit (QU) lacked adequate control over your testing operations and failed to ensure that you had suitable procedures. For example, your QU failed:\n\nTo adequately retain documentation for the review, approval, or rejection, of laboratory testing materials such as buffers, reagents, and media. There is a lack of assurance that testing materials used to conduct microbial testing meet all appropriate specifications before use of an incoming lot, and include evaluation of certificates of analysis (COA).\n\nTo ensure procedures were followed to document and retain records such as laboratory investigations, corrective action and preventive action plans (CAPA), and change controls. You told our investigators that you were not following a number of your standard operating procedures (SOPs).\n\nTo establish an adequate CGMP training program. You lacked appropriate resources to perform QU related functions and our inspection revealed basic CGMP violations.\n\nIn your response, you admit to not adhering to your SOPs and state that you will document receipt of all incoming testing materials and retain the associated documentation. You also committed to hiring a quality consultant to develop a CGMP training program and perform quality functions. However, your response is inadequate because you did not commit to conducting a retrospective review to ensure materials used for drug product testing were suitable for their intended use. In addition, you state that your lab technician will attend “21 CFR 820 training,” which is applicable to medical devices, but does not address the lack of CGMP training for drugs.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf .\n\nIn response to this letter, provide:\n\nA retrospective review of records for testing using received materials to assure correct materials were used and acceptable.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each lot and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\nAn independent summary of your retrospective review of records for (b)(4) years of testing using received materials to assure correct materials were used and acceptable.\n\n3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour laboratory records do not include complete testing data to support the analysis performed. For example, your records lack a statement of methods used for testing, a statement of the results of tests and how they compare to the established specifications, a record of all critical equipment used, and confirmation of compliance with testing conditions. Furthermore, you were unable to provide raw data to support the suitability of your alternative methods for each drug tested.\n\nAll CGMP-related data must be retained by all laboratories, including contract testing laboratories, to enable appropriate assessments and decisions by the QU and customers, and to demonstrate ongoing control.\n\nIn your response, you state that you will revise your records to include the missing information. Your response is inadequate because you make no commitment to retrospectively review prior testing for completeness, validity, or for errors.\n\nIn response to this letter, provide:\n\nA comprehensive independent assessment of documentation practices used throughout your laboratory operations to determine where documentation is insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn independent assessment that summarizes the potential impact on product quality of the inadequate documentation.\n\nResponsibilities of a Contract Testing Lab\n\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP when performing analytical work for your customers. Your laboratory role is critical to the pharmaceutical supply chain, and it is essential that you meet all CGMPs related to your function. As part of this responsibility, it is essential that you provide prompt, complete, and transparent analytical information to your customers (e.g., manufacturers) to enable them to handle their quality responsibilities related to batch evaluation and contractor oversight. This responsibility includes, but is not limited to, conveying to the customer any out-of-specification (OOS) investigations performed by your firm.\n\nFor additional information refer to FDA Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant (i.e., an independent third party) qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Identify your response with FEI# 3023533273.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nU.S. Food and Drug Administration\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I","Sure-Biochem Laboratories, LLC","sure-biochem-laboratories-llc-646619-03242023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsure-biochem-laboratories-llc-646619-03242023","2026-10-26T08:10:08.213568+00:00","2023-05-23","646619","Division of Pharmaceutical Quality Operations I","Tiffany Heigler","2026-08-20T01:06:32.524+00:00","Via Email","2023-03-24",4,{"510k":97,"classification":98,"enforcement":99,"event":100,"event_backfill":101,"pma":102,"warning_letter":103},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-16T04:00:38.924+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]